Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Potential Noninvasive Biomarker of EoE Disease Activity Identified

By LabMedica International staff writers
Posted on 24 May 2016
Researchers have identified a potential blood-based marker of disease activity for the severe and often painful food allergic disease eosinophilic esophagitis (EoE) – possibly leading to a blood test, which could spare EoE patients, often children, the discomfort and risk of the currently used invasive endoscopic monitoring procedures.

Researchers at the Cincinnati Center for Eosinophilic Disorders (CCED) of Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) led the study. “Adults and children with EoE can be on highly restricted diets of formula alone or only a few foods,” said Patricia C. Fulkerson, MD, PhD, senior study author, “One of the major obstacles to families participating in studies to introduce foods back into the child’s diet is the need for endoscopy after each food is tried to see whether or not it triggers disease activity.”

The disease activity of EoE is currently monitored using peak esophageal eosinophil count, which requires endoscopy to collect esophageal tissue biopsies. People with EoE, a lifelong disease, must continue monitoring disease activity, even after effective treatment with restricted diets or steroids. Treatment changes, such as reintroducing a single food, require additional endoscopic exams to assess for disease flare-ups.

Prior research has demonstrated that testing blood of EoE patients is not a clinically useful indication of active disease because eosinophil levels in blood do not correlate well with levels in the esophagus. This led the team to investigate a precursor cell to eosinophils, a lineage-committed eosinophil progenitor (EoP), as a potential marker. They found elevated EoP levels in the blood of pediatric patients with active EoE disease, suggesting a promising, blood-based marker.

The authors emphasize that additional research is needed to validate the marker before routine clinical use. “This clinical study is the first to investigate EoP levels in patients with EoE and identifies a potential new noninvasive biomarker,” said study author Vincent A. Mukkada, MD, physician at Cincinnati Children’s and CCED member, “This work is an essential step toward improving outcomes for patients with EoE. It will be followed by repeated testing of more patients and with sequential measurements of EoP levels in the same patient during different disease states.”

Allergic diseases have been on the rise over the past 20 years. The CCED team has previously reported that incidence of EoE is estimated at 1 of 1,000 people. Their research has also shown that EoE is caused by a combination of genetic and environmental factors, and is primarily mediated by an immunologic response to foods. The hallmark of EoE is swelling and inflammation in the esophagus, accompanied by high levels of eosinophils.

The study, by Morris DW et al, was published May 16, 2016, in the Journal of Allergy and Clinical Immunology.

Related Links:
Cincinnati Children’s Hospital Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.